Email this article 
Pleiotropic Effects of Sitagliptin in the Treatment of Type 2 Diabetes Mellitus Patients
Abstract
Background: Sitagliptin is a DPP-4 inhibitor that became available for use in Japan three years ago. This study was conducted to identify the pleiotropic effects of sitagliptin other than blood glucose lowering in Japanese type 2 diabetes mellitus patients.
Methods: A retrospective, observational study of 940 type 2 diabetes mellitus patients was conducted. The primary outcome measures were HbA1c, blood pressure, and lipid profiles measured at 0, 4, and 12 weeks of sitagliptin therapy.
Results: After 12 weeks of sitagliptin treatment, compared with baseline, HbA1c decreased 0.64% 0.86%; systolic blood pressure (SBP) and diastolic blood pressure (DBP) decreased significantly; and serum creatinine (Cr) and uric acid (UA) levels were mildly but significantly elevated. A correlation analysis of the changes in systolic blood pressure, diastolic blood pressure, creatinine, and uric acid (delta SBP,delta DBP, delta Cr, delta UA) from baseline to 12 weeks showed significant negative correlations between delta SBP and delta Cr, delta SBP and delta UA, and delta DBP and delta Cr. Total cholesterol and postprandial triglycerides were significantly decreased at both 4 and 12 weeks. Alkaline phosphatase (ALP) decreased significantly, and there was a significant positive correlation between changes in ALP and HbA1c.
Conclusions: Sitagliptin seems to be effective not only in lowering blood glucose but also in lowering blood pressure, lipid, and ALP levels. Sitagliptin appears to contribute to a Na-diuretic action due to GLP-1.
doi: http://dx.doi.org/10.4021/jocmr1061w